Quantcast

Latest Metastasis Stories

2014-09-29 23:08:39

This new genetic-based imaging technique is able to detect cancerous cells through expression of a gene called AEG-1. BETHESDA, MD (PRWEB) September 29, 2014 The very first sensitive and specific molecular imaging technique to detect bone metastases was recently developed by NFCR-funded scientist Paul B. Fisher, M.Ph., Ph.D., at the Virginia Commonwealth University Massey Cancer Center and VCU Institute of Molecular Medicine in collaboration with Martin G. Pomper, M.D., Ph.D., at the...

2014-09-29 12:28:40

ALBANY, New York, September 29, 2014 /PRNewswire/ -- According to a new market report published by Transparency Market Research "Circulating Circulating Tumor Cells (CTCs) Prognostic Technologies Market [Technologies: Tumor Cell Enrichment (Filtration, Centrifugation and Immunological & Immunomagnetic Methods) & Tumor Cell Detection (Molecular Methods and Optical Methods) and Applications: Prostate Cancer, Breast Cancer, Colorectal Cancer and Others] - Global Industry...

2014-09-29 08:30:18

BONN, Germany, September 29, 2014 /PRNewswire/ -- Newly published European Society for Medical Oncology (ESMO) clinical guidelines for the treatment of metastatic colorectal cancer (mCRC) endorse radioembolisation, specifically with Yttrium-90 resin microspheres, as a clinically proven technology to "prolong time to liver tumour progression" in mCRC patients who have failed to respond to available chemotherapy options. SIR-Spheres Y-90 resin microspheres, the lead...

2014-09-25 08:27:17

SAN DIEGO, Sept. 25, 2014 /PRNewswire/ -- GenomeDx Biosciences today announced that it has entered into a contractual agreement with MultiPlan, Inc. for diagnostic laboratory testing. The agreement includes GenomeDx Biosciences' participation in the MultiPlan Network, expanding access to the Decipher(®) Prostate Cancer Classifier to health plan members who access the more than 500,000 providers participating in the MultiPlan Network. The Decipher prostate cancer classifier directly...

2014-09-23 08:30:28

#MBCStrength Encourages Women Living with Metastatic Breast Cancer to Share their Strength and Inspiration with Others WILMINGTON, Del., Sept. 23, 2014 /PRNewswire/ -- More than 173,000 women in the United States are living with metastatic breast cancer and each has a story to tell. AstraZeneca is launching a nationwide photo-sharing campaign to provide them another way to share their inspiration, experiences and strengths with others. To view the multimedia assets associated with...

2014-09-18 23:05:34

Research conducted by a team of neurosurgeons and radiation oncologists from Allegheny Health Network, and presented this week at the American Society for Radiation Oncology annual meeting, has documented improved survival in patients with cancerous brain tumors who undergo both surgical removal of the tumors along with stereotactic radiosurgery. Pittsburgh, PA (PRWEB) September 18, 2014 Research conducted by a team of neurosurgeons and radiation oncologists from Allegheny Health Network...

2014-09-18 12:29:43

The Highest Percentage of Non-Prescribers Anticipate Prescribing Tafinlar and Mekinist Within the Next One to Three Months, According to Findings from Decision Resources Group BURLINGTON, Mass., Sept. 18, 2014 /PRNewswire/ -- Decision Resources Group finds that at one year post-launch in the United States, 54 percent of surveyed U.S. medical oncologists have prescribed GlaxoSmithKline's BRAF inhibitor Tafinlar for BRAF-mutation-positive unresectable or metastatic melanoma, compared with 49...

2014-09-17 04:20:02

Tokyo, Sept 17, 2014 - (JCN Newswire) - Eisai Co., Ltd. announced today that a series of abstracts highlighting the latest clinical data on Halaven(R) (generic name: eribulin mesylate; non-taxane microtubule dynamics inhibitor, "Halaven") and lenvatinib mesylate (generic name; selective inhibitor of receptor tyrosine kinases (RTKs) with a novel binding mode, "lenvatinib") will be presented during the 39th European Society for Medical Oncology (ESMO) Congress...

2014-09-14 23:00:36

A study led by University of Colorado Cancer Center published today in the journal Nature uses a novel approach to target the activation of a protein that drives some cancers. AURORA, Colo. (PRWEB) September 14, 2014 When active, the protein called Ral can drive tumor growth and metastasis in several human cancers including pancreatic, prostate, lung, colon and bladder. Unfortunately, drugs that block its activity are not available. A study published today in the journal Nature uses a...

2014-09-08 08:31:27

SAN DIEGO and PRINCETON, N.J., Sept. 8, 2014 /PRNewswire/ -- Aethlon Medical, Inc. (NASDAQ:OTCQB:AEMD), and its diagnostic subsidiary, Exosome Sciences, Inc. (ESI), announced today that ESI researchers have developed and initially validated a lectin-based diagnostic platform that is able to isolate exosome-based biomarkers underlying a broad-spectrum of oncology indications. Aethlon Medical develops targeted therapeutic devices to address infectious disease, cancer and other...


Word of the Day
cacodemon
  • An evil spirit; a devil.
  • A nightmare.
  • In astrology, the twelfth house of a scheme or figure of the heavens: so called from its signifying dreadful things, such as secret enemies, great losses, imprisonment, etc.
'Cacodemon' comes from a Greek term meaning 'evil genius.'
Related